W. Abdallah, Morsi5; Larsen, Nanna5; Grove, Jakob8; Bonefeld-Jørgensen, Eva Cecilie9; Nørgaard-Pedersen, Bent5; M. Hougaard, David5; L. Mortensen, Erik7
1 Department of Public Health - Centre for Arctic Health, Department of Public Health, Health, Aarhus University2 Department of Bioscience - Arctic Research Centre, Bartholins Allé, Department of Bioscience, Science and Technology, Aarhus University3 Department of Biomedicine - Department of Human Genetics, Department of Biomedicine, Health, Aarhus University4 Bioinformatics Research Centre (BiRC), Science and Technology, Aarhus University5 Department of Clinical Biochemistry and Immunology, Statens Serum Institute6 Department of Biomedicine - Forskning og uddannelse, Øst, Department of Biomedicine, Health, Aarhus University7 Institute of Public Health and Center for Healthy Aging, University of Copenhagen8 Department of Biomedicine - Forskning og uddannelse, Øst, Department of Biomedicine, Health, Aarhus University9 Department of Public Health - Centre for Arctic Health, Department of Public Health, Health, Aarhus University
Findings from a Danish historic birth cohort follow-up study
A potential role of chemokines in the pathophysiology of Autism Spectrum Disorders (ASDs) has been previously suggested. In a recent study we examined levels of three inflammatory chemokines (MCP-1, MIP-1a and RANTES) in samples of amniotic fluid of children diagnosed later in life with ASD and controls frequency-matched to cases on gender and year of birth. In this follow-up study, levels of the same chemokines were analyzed postnatally in dried blood spot samples from the same subjects utilizing the Danish Newborn Screening Biobank. Crude estimates showed decreased levels of RANTES. In the adjusted estimates, no differences were found in levels of the three examined chemokines in ASD cases compared to controls. Our findings may cautiously suggest an altered cell-mediated immunity during the early neonatal period in ASD. Further research is needed to examine the relationship between maternal/fetal and neonatal chemokine levels and their role in ASD.